PC方案同步放化疗治疗局部晚期肺腺癌的近期和远期疗效分析

李智颖　　柳彬

[摘要] 目的 探討PC方案同步放化疗应用于局部晚期肺腺癌患者的临床效果，并评价其对患者生存率的影响。方法 选取2014年3月至2017年1月我院收治的局部晚期肺腺癌患者89例作为研究对象，采用随机数字表法将其分为PC组（n=46）和对照组（n=43），其中对照组患者实施DC方案化疗，PC组患者实施PC方案同步放化疗。观察两组患者的近期疗效、不良反应及生存率。 结果 PC组患者总有效率为89.13%，显著高于对照组的67.44%，差异有统计学意义（χ2=6.226，P<0.05）;PC组患者不良反应总发生率为17.39%，显著低于对照组的41.86%，差异有统计学意义（P<0.05）。出院后2年，PC组的生存率为86.96%，显著高于对照组的69.77%，差异有统计学意义（χ2=3.911，P<0.05）;出院后3年，PC组生存率为78.26%，显著高于对照组的51.16%，差异有统计学意义（χ2=7.190，P<0.05）。 结论 PC方案同步放化疗能明显改善局部晚期肺腺癌患者的近期疗效及远期疗效。

[关键词] PC方案同步放化疗;局部晚期肺腺癌;近期疗效;远期疗效

[中图分类号] R734.2          [文献标识码] B          [文章编号] 1673-9701（2021）13-0091-04

Short-term and long-term efficacy analysis of concurrent radiotherapy and chemotherapy with PC regimen for locally advanced lung adenocarcinoma

LI Zhiying1   LIU Bin2

1.Department of Medical Oncology， Hongda Hospital of Jiamusi University， Jiamusi   154002， China; 2.Department of Oncology， Jiamusi Hospital of Traditional Chinese Medicine in Heilongjiang Province， Jiamusi   154002， China

[Abstract] Objective To investigate the clinical effect of concurrent radiotherapy and chemotherapy with PC regimen in patients with locally advanced lung adenocarcinoma（ALA）， and to evaluate its influence on the survival rate of patients. Methods A total of 89 patients with locally ALA admitted to our hospital from March 2014 to January 2017 were selected as the research objects. They were divided into the PC group（n=46） and the control group（n=43） by random number table method. The control group was received DC regimen with chemotherapy and the PC group was received PC regimen with concurrent radiotherapy and chemotherapy. The short-term curative effect， adverse reactions and survival rate between the two groups were observed and compared. Results The total effective rate was 89.13% in the PC group， which was significantly higher than that of 67.44% in the control group， with significant difference （χ2=6.226， P<0.05）. The total adverse reaction rate in the PC group was 17.39%， which was significantly lower than that of 41.86% in the control group， with significant difference（P<0.05）. Two years after discharge， the survival rate in the PC group was 86.96%， which was significantly higher than that of 69.77% in control group， with significant difference（χ2=3.911， P<0.05）. Three years after discharge， the survival rate was 78.26% in the PC group， which was significantly higher than that of 51.16% in the control group， with significant difference（χ2=7.190， P<0.05）. Conclusion PC regimen with concurrent radiotherapy and chemotherapy can significantly improve the short-term and long-term efficacy of patients with locally ALA.

[Key words] PC regimen with concurrent radiotherapy and chemotherapy; Locally advanced lung adenocarcinoma; Short-term efficacy; Long-term efficacy

肺腺癌是一種常见的肺癌，是发生于支气管黏膜上皮的非小细胞性肺癌[1]。随着环境污染日益严重，流行病学资料显示，肺腺癌的发病率逐年上升，其死亡率占我国癌症死亡率的第一位[2-3]。同期放化疗已成为局部晚期肺腺癌的标准临床治疗模式，但同步化疗的选择仍没有定论，因此寻找最优的同步化疗方案是目前研究者主要任务。有研究表明，PC方案同步放化疗多用于不能忍受手术的肺腺癌患者。有学者对100例局部晚期肺腺癌患者进行研究，指出PC方案同步放化疗能有效改善患者近期疗效。有研究显示，采用分组对照的方式，对分别采用PC方案同步放化疗、DC方案化疗进行的82例局部晚期肺腺癌患者的近期疗效及远期疗效进行对比研究，结果显示PC方案同步放化疗优于DC方案化疗。基于此，笔者结合自身临床实践，选取我院收治的89例局部晚期肺腺癌患者作为研究对象，对PC方案同步放化疗应用于局部晚期肺腺癌患者的效果进行研究，现报道如下。……